Results 61 to 70 of about 2,106 (155)

Darbepoetin versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment

Clinical Medicine Insights: Oncology, 2008
Introduction Anemia is the most frequent hematological disturbance in cancer patients, with prevalence between 30% and 90%, depending on the type of tumor, the antitumor treatment, and other factors (infection, malnutrition, bleeding, tumor infiltration ...
Pilar M Samper Ots, Concepción López Carrizosa, Aurora Rodríguez Pérez, Juan De Dios Saez Garrido, José M Delgado Pérez   +4 more
doaj   +1 more source

Erythropoiesis stimulating agents approaches to modulate activity

Biologics: Targets & Therapy, 2013
Angus M Sinclair Amgen Inc, Thousand Oaks, CA, USA Abstract: Recombinant human erythropoietin (rHuEPO), such as the approved agents epoetin alfa and epoetin beta, has been used successfully for over 20 years to treat anemia in millions of patients ...
Sinclair AM
doaj  

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Comparative effectiveness of darbepoetin vs other agents in chronic kidney disease-related anemia: a systematic review and network meta-analysis

BMC Nephrology
Introduction In the advanced stages of chronic kidney disease (CKD), anemia impacts 78.9% to 96.5% of patients. Darbepoetin is utilized for the treatment of anemia associated with chronic kidney disease (CKD).
Muhammad Faique Hassan, Muhammad Shaheer Bin Faheem, Shamikha Cheema, Fathimathul Henna, Saman Javid, M. Rafiqul Islam, Insha Habib, Muhammad Usman, Yousif Hameed Kurmasha, Sumaya Samadi, Yaqub Nadeem Mohammad   +10 more
doaj   +1 more source

Redefining anaemia management in CKD: comparative insights on desidustat, roxadustat, and molidustat as oral HIF-PH inhibitors

Clinical Medicine
Introduction: Anaemia affects over 50% of advanced chronic kidney disease (CKD) patients, increasing cardiovascular mortality. Traditional erythropoiesis-stimulating agents (ESAs) require injections and carry risks, such as hypertension and ...
Kaandeeban Mohanraj, Cheryl Singla, Vidhya Mohanraj, Vishnuvardan Venkatramanan   +3 more
doaj   +1 more source

Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients.

PLoS ONE, 2016
Anemia management, based on erythropoiesis stimulating agents (ESA) and iron supplementation, has become an increasingly challenging problem in hemodialysis patients.
Carlo Barbieri, Elena Bolzoni, Flavio Mari, Isabella Cattinelli, Francesco Bellocchio, José D Martin, Claudia Amato, Andrea Stopper, Emanuele Gatti, Iain C Macdougall, Stefano Stuard, Bernard Canaud   +11 more
doaj   +1 more source

Darbepoetin Use for the Treatment of Anemia in Hemodialysis Patients in Saudi Arabia

Saudi Journal of Kidney Diseases and Transplantation, 2006
Erythropoietin replacing proteins have improved patient outcomes and quality of life. Darbepoetin has a 3-fold longer half-life than recombinant human erythropoietin (rHuEPO).
Shaheen Faissal, Akeel Nabila, Alfi Adnan, Harbi Ali, Tarif Nauman, Souqiyyeh Mohammad   +5 more
doaj  

Characterization of Neutropenia in Preterm Neonates Following Administration of Darbepoetin Alfa. [PDF]

J Pediatr Pharmacol Ther, 2023
Andrews N, Friedman S, Dunham M, Dean R, Chabra S.   +4 more
europepmc   +1 more source

Exacerbation of Diabetic Retinopathy following Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor Administration: A Case Report

Case Reports in Ophthalmology
Introduction: Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors, used in the treatment of renal anemia, hold the potential to increase the production of vascular endothelial growth factors.
Nobuaki Ariyoshi, Fumiaki Higashijima, Makiko Wakuta, Tadahiko Ogata, Manami Ohta, Kazuhiro Kimura   +5 more
doaj   +1 more source

Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial. [PDF]

Clin Exp Nephrol, 2023
Maruyama S, Kurasawa S, Hayashi T, Nangaku M, Narita I, Hirakata H, Tanabe K, Morita S, Tsubakihara Y, Imai E, Akizawa T, PREDICT Investigators.   +11 more
europepmc   +1 more source